A successful, earlier-stage trial with its oral, serotonin-reducing therapy for carcinoid syndrome helped Lexicon Pharmaceuticals Inc. figure out dosing in a Phase III study, the start of which made news at the same time that the company disclosed results from the Phase II experiment with LX-1032, or telotristat etiprate.